Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Mayo Clinic reports breakthrough treatment for breast cancer

20.10.2005


Concurrent NCCTG and NSABP studies find trastuzumab best for women with HER2

In a joint paper, co-authored by Mayo Clinic’s Edith Perez, M.D., and Edward Romond, M.D., of the National Surgical Adjuvant Breast and Bowel Project (NSABP), researchers report complete and combined results of two trials comparing adjuvant chemotherapy with or without concurrent trastuzumab treatment in women with surgically removed HER2-positive breast cancer. The studies showed trastuzumab (Herceptin®) therapy to be highly superior to standard treatment, reducing recurrence of cancer by half. The findings will be published in the Oct. 20, 2005, issue of The New England Journal of Medicine.

"Herceptin has changed the treatment of breast cancer," says Dr. Perez, who is the co-director of Mayo Clinic’s Multidisciplinary Breast Clinic in Jacksonville, Fla. "When we started this study, I knew in my heart results would be positive, but this by far exceeded my expectations."



Of the 2,043 patients enrolled in NSABP trial B-31 and 1,633 patients enrolled in the two reported treatment groups of the North Central Cancer Treatment Group (NCCTG ) trial N9831 by the end of 2004, complete follow-up information was available on 3,351 patients. Two hundred sixty-one women in the control group (1,679 patients) had a recurrence of breast or other primary cancer as compared to 133 in the group receiving trastuzumab. At three years, 90.4 percent of women receiving trastuzumab were disease free, compared to 81.5 percent of women in the control group. There also was a measurable reduction in the development of other non-breast primary cancers in the B-31 trial for women receiving trastuzumab. Overall survival also appeared to be impacted, with only 62 deaths in the trastuzumab group as compared with 92 in the control group.

Dr. Perez and her co-investigators found convincing evidence that women with HER2-positive breast cancer can now be treated more effectively. "A million women each year are diagnosed with breast cancer throughout the world, and approximately 25 percent of them have HER2 tumors," said Dr. Perez. "To be able to find a treatment that impacts the lives of so many is a huge success for the cancer research community."

The NCCTG trial N9831, of which Dr. Perez was the primary investigator, was a cooperative effort with the Eastern Cooperative Oncology Group (ECOG), the Southwest Oncology Group (SWOG), and the Cancer and Leukemia Group B (CALGB). It compared three chemotherapy regimens, two that included trastuzumab therapy -- one dosage concurrent with weekly paclitaxel, the other after completion of paclitaxel. The NSABP trial B-31 compared one chemotherapy regimen against the same regimen with weekly trastuzumab and tri-weekly (or weekly) paclitaxel. Investigators determined that the treatments being compared were similar, and results from the two studies were combined to form a joint analysis, excluding the NCCTG N9831 trial group that looked at trastuzumab administered sequentially after paclitaxel.

In addition to Dr. Perez, members of the NCCTG and Mayo Clinic research team included Vera Suman, Ph.D.; Thomas Pisansky, M.D.; Leila Kutteh, M.D.; Daniel Visscher, M.D.; Robert Jenkins, M.D., Ph.D.; Shaker Dakhil, M.D.; Wilma Lingle, Ph.D.; and James Ingle, M.D. Other collaborating researchers on N9831 included Nancy Davidson, M.D. (ECOG); Silvana Martino, D.O. (SWOG); and Peter Kaufman, M.D. (CALGB).

Elizabeth Zimmermann | EurekAlert!
Further information:
http://www.mayo.edu
http://www.mayoclinic.com

More articles from Health and Medicine:

nachricht New malaria analysis method reveals disease severity in minutes
14.08.2017 | University of British Columbia

nachricht New type of blood cells work as indicators of autoimmunity
14.08.2017 | Instituto de Medicina Molecular

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

Im Focus: Scientists improve forecast of increasing hazard on Ecuadorian volcano

Researchers from the University of Miami (UM) Rosenstiel School of Marine and Atmospheric Science, the Italian Space Agency (ASI), and the Instituto Geofisico--Escuela Politecnica Nacional (IGEPN) of Ecuador, showed an increasing volcanic danger on Cotopaxi in Ecuador using a powerful technique known as Interferometric Synthetic Aperture Radar (InSAR).

The Andes region in which Cotopaxi volcano is located is known to contain some of the world's most serious volcanic hazard. A mid- to large-size eruption has...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

New thruster design increases efficiency for future spaceflight

16.08.2017 | Physics and Astronomy

Transporting spin: A graphene and boron nitride heterostructure creates large spin signals

16.08.2017 | Materials Sciences

A new method for the 3-D printing of living tissues

16.08.2017 | Interdisciplinary Research

VideoLinks
B2B-VideoLinks
More VideoLinks >>>